遗传性球形红细胞增多症 中国就医指南

Hereditary Spherocytosis (HS) is a common inherited hemolytic anemia characterized by the presence of spherical, fragile red blood cells (spherocytes) that are prematurely destroyed in the spleen. It results from mutations in genes encoding proteins of the erythrocyte membrane skeleton—including ANK1 (ankyrin), SPTB (spectrin beta), SPTA1 (spectrin alpha), SLC4A1 (band 3), and EPB42 (protein 4.2)—leading to loss of membrane surface area, reduced deformability, and increased osmotic fragility. This structural defect impairs red blood cell survival, causing chronic extravascular hemolysis primarily in the reticuloendothelial system, especially the spleen. Clinical manifestations vary widely: mild cases may be asymptomatic or present only with compensated hemolysis and mild anemia; moderate cases often feature fatigue, pallor, intermittent jaundice, and splenomegaly; severe forms can involve profound anemia, growth retardation in children, aplastic or megaloblastic crises (often triggered by parvovirus B19 infection), gallstones (due to chronic bilirubin overload), and cardiac complications from long-standing anemia. HS has an estimated prevalence of 1 in 2,000 to 1 in 5,000 individuals in populations of Northern European descent, though underdiagnosis is common globally. It follows autosomal dominant inheritance in ~75% of cases, with autosomal recessive and de novo variants accounting for the remainder. Risk factors include family history (strongest predictor), consanguinity (increasing risk for recessive forms), and certain ethnic backgrounds—though it occurs across all ethnic groups. Quality of life impact is multifaceted: children may experience school absenteeism due to fatigue or crisis episodes; adults report reduced exercise tolerance, chronic fatigue, anxiety around hemolytic crises, and psychosocial burden related to lifelong monitoring and surgical decisions (e.g., splenectomy). Gallstone-related pain and hospitalizations further impair daily functioning. While splenectomy remains highly effective in reducing hemolysis and transfusion dependence, it carries lifelong risks of overwhelming post-splenectomy infection (OPSI), necessitating vaccination and antibiotic prophylaxis. Emerging non-surgical management—including folic acid supplementation, phototherapy for neonatal hyperbilirubinemia, cholecystectomy for symptomatic gallstones, and emerging targeted therapies under investigation—supports individualized, multidisciplinary care led by hematologists. Early diagnosis via peripheral blood smear, osmotic fragility testing, flow cytometry (EMA binding test), and genetic confirmation enables timely intervention and counseling, significantly improving long-term outcomes and quality of life.

# 遗传性球形红细胞增多症（HS）治疗方案与费用明细（血液科）

一、非手术/保守治疗

适用于轻度贫血（Hb ≥100 g/L）、无溶血危象、脾功能正常者：

• •叶酸补充：5 mg/d口服，年药费约30–80元；
• •定期监测：血常规+网织红细胞+胆红素+LDH（每3–6个月），单次检验费120–180元；
• •避免诱发因素：感染防控、禁用磺胺类药物；无额外治疗费。

二、手术治疗（脾切除术）

适应证：中重度贫血（Hb <100 g/L）、反复溶血危象、胆石症或生长发育迟滞。

• •腹腔镜脾切除术（首选）：术前检查（血型、凝血、腹部超声、心电图等）800–1,200元；手术+麻醉+住院（7–10天）总费用28,000–38,000元；
• •开腹脾切除术（仅限腹腔粘连或巨大脾）：总费用32,000–45,000元。

三、特殊/并发症治疗

• •溶血危象期输血：红细胞悬液1U（200 mL）280–350元（含配血费），单次≤2U；
• •胆结石合并症：需同期胆囊切除，增加费用12,000–18,000元；
• •再生障碍危象（Parvovirus B19感染）：静脉免疫球蛋白（IVIG）2.5 g/d×2天，药费4,500–6,000元。

四、方案快速选择指南

• •预算有限/轻症：保守治疗+规律随访（年支出＜500元）；
• •中重度患者（首选根治）：腹腔镜脾切除（性价比最优，治愈率＞90%）；
• •儿童＜6岁/免疫未成熟：暂缓手术，强化预防接种+严密监测；
• •合并胆石或危象频发：联合胆囊切除+脾切除，一步到位。